| scholarly article | Q13442814 |
| P50 | author | Eva Harris | Q5415063 |
| Aravinda M. de Silva | Q89242260 | ||
| S Kyle Austin | Q115216876 | ||
| Scott A Smith | Q115654143 | ||
| Nurgun Kose | Q115654145 | ||
| Kristie D Ibarra | Q115654198 | ||
| Michael S. Diamond | Q28051146 | ||
| James E. Crowe, Jr. | Q37366747 | ||
| Soila Sukupolvi-Petty | Q46150876 | ||
| P2093 | author name string | Benjamin J Doranz | |
| Jennifer M Pfaff | |||
| Kristen M Kahle | |||
| Xiaoxiao Xiang | |||
| A Ruklanthi de Alwis | |||
| P2860 | cites work | The global distribution and burden of dengue | Q24628768 |
| Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention | Q24684689 | ||
| Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification | Q27315772 | ||
| Infection of human cells by dengue virus is modulated by different cell types and viral strains | Q27469687 | ||
| Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells | Q27469935 | ||
| Flow cytometry-based assay for titrating dengue virus | Q27470044 | ||
| Serotype-specific detection of dengue viruses in a fourplex real-time reverse transcriptase PCR assay | Q27472605 | ||
| Antibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope Protein | Q27477718 | ||
| Comparison of Plaque- and Flow Cytometry-Based Methods for Measuring Dengue Virus Neutralization | Q27484661 | ||
| Induction of Epitope-Specific Neutralizing Antibodies against West Nile Virus | Q27484980 | ||
| Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes | Q27485031 | ||
| Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II | Q27486409 | ||
| Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus | Q27486788 | ||
| Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens | Q27488243 | ||
| Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody | Q27489654 | ||
| Enhanced Infection of Liver Sinusoidal Endothelial Cells in a Mouse Model of Antibody-Induced Severe Dengue Disease | Q27490947 | ||
| Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins | Q27649830 | ||
| Structural Basis of Differential Neutralization of DENV-1 Genotypes by an Antibody that Recognizes a Cryptic Epitope | Q27674417 | ||
| The structural basis for serotype-specific neutralization of dengue virus by a human antibody | Q27681306 | ||
| Cross-reacting antibodies enhance dengue virus infection in humans | Q28281588 | ||
| Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century | Q29616264 | ||
| Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein | Q29618169 | ||
| A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein | Q33802834 | ||
| In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection | Q33945441 | ||
| A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus | Q33954392 | ||
| A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial | Q33988937 | ||
| Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. | Q34120070 | ||
| Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay | Q34123956 | ||
| Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop | Q34306877 | ||
| Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. | Q34607919 | ||
| Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms | Q35531167 | ||
| A fusion-loop antibody enhances the infectious properties of immature flavivirus particles | Q35531326 | ||
| Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors | Q35844406 | ||
| Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions | Q35982791 | ||
| Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics | Q36846290 | ||
| Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection | Q37123259 | ||
| High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection | Q37336440 | ||
| The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity | Q37448171 | ||
| Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera | Q40298293 | ||
| Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection | Q40302703 | ||
| Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus | Q40441111 | ||
| Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice | Q40539730 | ||
| Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. | Q40698415 | ||
| Antibody-enhanced dengue virus infection in primate leukocytes | Q40884212 | ||
| P433 | issue | 6 | |
| P921 | main subject | antibody | Q79460 |
| monoclonal antibody | Q422248 | ||
| Dengue virus | Q476209 | ||
| P304 | page(s) | e00873-13 | |
| P577 | publication date | 2013-11-19 | |
| P1433 | published in | mBio | Q15817061 |
| P1476 | title | The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein | |
| P478 | volume | 4 |
| Q90051339 | A Novel Neutralizing Antibody Targeting a Unique Cross-Reactive Epitope on the hi Loop of Domain II of the Envelope Protein Protects Mice against Duck Tembusu Virus |
| Q97545865 | A complex between the Zika virion and the Fab of a broadly cross-reactive neutralizing monoclonal antibody revealed by cryo-EM and single particle analysis at 4.1 Å resolution |
| Q37012203 | A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection |
| Q26860116 | A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes |
| Q35138111 | A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins |
| Q35654743 | A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus |
| Q36205859 | A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies |
| Q28804076 | A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis |
| Q47194469 | A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice |
| Q89783355 | Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity |
| Q41676281 | Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes |
| Q47143843 | Antibody therapies for the prevention and treatment of viral infections. |
| Q47592202 | Antibody-dependent enhancement of severe dengue disease in humans |
| Q92662548 | Antiviral Effectors and Gene Drive Strategies for Mosquito Population Suppression or Replacement to Mitigate Arbovirus Transmission by Aedes aegypti |
| Q40173610 | Broad and strong: the ultimate antibody to dengue virus |
| Q92689558 | Broad dengue neutralization in mosquitoes expressing an engineered antibody |
| Q83225458 | Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics |
| Q59349143 | Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes |
| Q39535403 | Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development |
| Q35758626 | Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies |
| Q27654848 | Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity |
| Q33425879 | Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection |
| Q33798068 | Delineating antibody recognition against Zika virus during natural infection |
| Q26247258 | Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus |
| Q40045875 | Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys |
| Q40044088 | Dengue Virus Glycosylation: What Do We Know? |
| Q36434210 | Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site |
| Q90286486 | Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies |
| Q42985743 | Dengue vaccine: hypotheses to understand CYD-TDV-induced protection |
| Q52334283 | Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope. |
| Q35294150 | Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera |
| Q28729764 | Dengue: knowledge gaps, unmet needs, and research priorities |
| Q47558158 | Development of Antibody Therapeutics against Flaviviruses |
| Q38609515 | Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward |
| Q33638496 | Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop |
| Q91957254 | Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era? |
| Q63248501 | Envelope protein glycosylation mediates Zika virus pathogenesis |
| Q36597801 | Evolutionarily Successful Asian 1 Dengue Virus 2 Lineages Contain One Substitution in Envelope That Increases Sensitivity to Polyclonal Antibody Neutralization |
| Q36878970 | Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1. |
| Q39375868 | Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy |
| Q35850197 | Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus |
| Q26700001 | MEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus |
| Q54217627 | Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. |
| Q54265465 | Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus. |
| Q38646923 | New insights into the immunopathology and control of dengue virus infection |
| Q91842996 | Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes |
| Q47549097 | Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo |
| Q40136145 | Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies. |
| Q55338916 | Potent Neutralization Ability of a Human Monoclonal Antibody Against Serotype 1 Dengue Virus. |
| Q59353226 | Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine |
| Q40040450 | Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine |
| Q66679798 | Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes |
| Q28119679 | Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection |
| Q99731978 | Protective and enhancing interactions among dengue viruses 1-4 and Zika virus |
| Q30395028 | Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies. |
| Q90733120 | Seeking Flavivirus Cross-Protective Immunity |
| Q104617064 | Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003 |
| Q40056291 | Structural Basis of Zika Virus-Specific Antibody Protection |
| Q47548107 | Structural basis for neutralization of Japanese encephalitis virus by two potent therapeutic antibodies. |
| Q26700120 | Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope |
| Q46261471 | Structures and Functions of the Envelope Glycoprotein in Flavivirus Infections. |
| Q24067948 | Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody |
| Q27468788 | Systematic Bioinformatic Approach for Prediction of Linear B-Cell Epitopes on Dengue E and prM Protein |
| Q26995782 | The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response |
| Q38994574 | The mechanistic role of antibodies to dengue virus in protection and disease pathogenesis |
| Q47262746 | The use of databases, data mining and immunoinformatics in vaccinology: where are we? |
| Q91741475 | Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design |
| Q39172722 | Vaccines licensed and in clinical trials for the prevention of dengue |
| Q60046445 | Viral-Induced Enhanced Disease Illness |
| Q26314715 | Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies |
| Q38157725 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine |
| Q40047887 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials |
Search more.